论文部分内容阅读
目的:观察芪苈强心胶囊对心力衰竭患者血浆N-末端脑钠肽前体(NT-pro BNP)及高敏C-反应蛋白(hs-CRP)的影响。方法:将108例慢性心力衰竭患者随机分为治疗组58例和对照组50例,治疗组予西医常规治疗结合芪苈强心胶囊治疗,对照组予西医常规治疗。治疗2周后比较两组患者心功能、血浆NT-pro BNP及hs-CRP水平。结果:治疗后两组左心室舒张末期内径、心排出量、左室射血分数均较治疗前改善,治疗组改善的程度优于对照组(P<0.05);hs-CRP和NT-pro BNP在心功能越差的患者中其浓度越高(P<0.05)。治疗后治疗组血浆NT-pro BNP及hs-CRP水平均低于对照组(P<0.05);治疗组临床疗效优于对照组(P<0.05)。结论:芪苈强心胶囊能显著改善心力衰竭患者心脏舒缩功能,降低其血浆NT-pro BNP及hs-CRP水平。
Objective: To observe the effect of Qili Qiangxin capsule on plasma N-terminal pro BNP and hs-CRP in patients with heart failure. Methods: A total of 108 patients with chronic heart failure were randomly divided into treatment group (58 cases) and control group (50 cases). The treatment group was treated with conventional Western medicine combined with Qili Qiangxin Capsule, and the control group was treated with conventional Western medicine. After 2 weeks of treatment, the cardiac function, plasma NT-pro BNP and hs-CRP levels were compared between the two groups. Results: The left ventricular end-diastolic diameter, cardiac output and left ventricular ejection fraction were improved in both groups after treatment compared with those before treatment. The treatment group improved more than the control group (P <0.05). The levels of hs-CRP and NT-pro BNP Patients with worse heart function had higher concentrations (P <0.05). The plasma levels of NT-pro BNP and hs-CRP in the treatment group were lower than those in the control group (P <0.05). The clinical efficacy of the treatment group was better than that of the control group (P <0.05). Conclusion: Qili Qiangxin Capsule can significantly improve cardiac function in patients with heart failure and reduce their plasma levels of NT-pro BNP and hs-CRP.